Longnecker R, Miller C L, Tomkinson B, Miao X Q, Kieff E
Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.
J Virol. 1993 Aug;67(8):5068-74. doi: 10.1128/JVI.67.8.5068-5074.1993.
A recombinant Epstein-Barr virus (EBV) was constructed, with a positive-selection marker inserted at the site of a deletion of a DNA segment which encodes the first five transmembrane domains of LMP2A and LMP2B. Despite the mutation, the mutant recombinant EBV was able to initiate and maintain primary B-lymphocyte growth transformation in vitro. Cells transformed with the mutant recombinant were not different from wild-type virus transformants in initial or long-term outgrowth, sensitivity to limiting cell dilution, or serum requirement. Expression of EBNA1, EBNA2, EBNA3A, EBNA3C, and LMP1 and permissivity for lytic EBV infection were also unaffected by the LMP2 deletion mutation. These results complete the molecular genetic studies proving LMP2 is dispensable for primary B-lymphocyte growth transformation, latent infection, and lytic virus replication in vitro.
构建了一种重组爱泼斯坦-巴尔病毒（EBV），在编码LMP2A和LMP2B前五个跨膜结构域的DNA片段缺失位点插入了一个阳性选择标记。尽管发生了突变，但突变重组EBV仍能够在体外启动并维持原代B淋巴细胞的生长转化。用突变重组体转化的细胞在初始或长期生长、对有限细胞稀释的敏感性或血清需求方面与野生型病毒转化体没有差异。EBNA1、EBNA2、EBNA3A、EBNA3C和LMP1的表达以及对EBV裂解感染的允许性也不受LMP2缺失突变的影响。这些结果完成了分子遗传学研究，证明LMP2对于原代B淋巴细胞的生长转化、潜伏感染和体外裂解病毒复制是可有可无的。
Zotero 插件
